CHICAGO, March 14, 2025 — Nimblemind.ai, an AI-powered data infrastructure platform designed to help healthcare providers structure and leverage their clinical data, has secured $2.5 million in funding to accelerate its mission. The round was led by Bread & Butter Ventures, and included participation from Great Oaks Venture Capital, SpringTime Ventures, Stone Mountain Ventures, Victorum Capital, Techstars, and strategic HC angel investors committed to transforming healthcare through AI-driven data infrastructure.

The funding will enable Nimblemind.ai to accelerate its mission of making unstructured healthcare data AI-ready. By curating and labeling clinical datasets, the company is addressing one of the biggest challenges in healthcare AI—access to high-quality, structured multi-modal datasets.

“We are at an inflection point where AI can revolutionize healthcare, but without well-structured, specialty-specific data, its full potential remains untapped,” said Pi Zonooz, CEO & Co-Founder of Nimblemind.ai. “Our platform ensures that healthcare providers can unlock the value of their data for AI while maintaining sovereignty and compliance. We put the healthcare provider in the driver seat of their AI future.”

Nimblemind.ai has secured partnerships with multiple healthcare organizations in the US and Asia. The company’s proprietary approach enables clinicians to transform raw patient data into structured, AI-ready formats, paving the way for better decision-making, predictive analytics, and non-clinical revenue opportunities. “Nimblemind.ai is unlocking the power of AI in healthcare. By organizing and curating data from our EMR, patient surveys, and wearable devices, they are helping us identify patient interventions more effectively. This kind of AI-driven insight is the future of personalized, proactive care,” said Lynn M Madden, PhD, CEO of APT Foundation. 

“We believe that transforming healthcare represents perhaps the single most significant application of artificial intelligence in our time, and Nimblemind.ai is building the essential foundation to realize this potential,” said Mary Grove, Managing Director of Bread & Butter Ventures. “Their platform empowers healthcare providers with everything from sophisticated clinical decision support to streamlined operations and personalized patient care. With their exceptional vision and technical expertise, the Nimblemind team is uniquely positioned to lead this revolution.”

With this funding, Nimblemind.ai plans to expand its specialty-specific AI models, enhance its platform’s capabilities, and onboard more healthcare providers seeking to leverage AI for better patient outcomes.

For more information about Nimblemind.ai, visit www.nimblemind.ai

SOURCE Nimblemind.ai

• Approximately $12 million additional financing led by Shenzhen Capital Group (SCGC), with participation from existing investor Morningside Ventures, and new investors Leader Venture Investment (SZTI) and Hefei Sci-Tec Venture Capital (HFST).
• Cash runway extended into the second half of 2026

NEW YORK and SUZHOU, China, March 14, 2025 — Accropeutics Inc. (Accropeutics), a clinical-stage biotechnology company pioneering the development of novel therapeutics that target molecular mechanisms of regulated cell death for immune mediated diseases, today announced the closing of its $12 million Series B Plus financing. The round was led by Shenzhen Capital Group (SCGC), an existing investor, with participation from Morningside Ventures, also an existing investor, and new investors Leader Venture Investment (SZTI) and Hefei Sci-Tec Venture Capital (HFST).

The proceeds from the Series B Plus financing will be used to generate more clinical data for AC-101, a RIPK2 inhibitor, in an ongoing Phase Ib clinical trial for patients with Ulcerative Colitis (UC). Accropeutics’ other clinical-stage assets include AC-201, a selective TYK2/JAK1 inhibitor, currently in an ongoing Phase II trial for patients with moderate-to-severe Psoriasis, and for multiple additional indications; and AC-003, a RIPK1 inhibitor, currently in an ongoing Phase Ib trial for patients with acute Graft-versus-Host Disease (aGvHD). The company also has multiple I&I assets in the pre-clinical stage.

Dr. Xiaohu (Jason) Zhang, Co-founder and CEO of Accropeutics, stated: ” With this round of financing, we are able to continue advancing our lead programs and solidify our position as an innovative, multi-program, clinical-stage biotech company. I am grateful to our existing and new investors, who share our vision that we can transform the treatment landscape for a wide range of I&I diseases with potentially best-in-class therapies. “

About Accropeutics

Accropeutics Inc. is a clinical-stage biotechnology company pioneering the discovery, development and commercialization of novel therapeutics for immune mediated inflammatory disease, by targeting molecular mechanisms of regulated cell death. The company has a robust portfolio of innovative compounds in various stages of development, ranging from lead optimization to clinical testing. AC-101, a selective RIPK2 inhibitor, has completed Phase I clinical trials in Australia and China, and is currently undergoing a Phase Ib trial for Ulcerative Colitis (UC). AC-201, a selective TYK2/JAK1 inhibitor, has completed Phase I study in Australia and China, and is currently undergoing a Phase II trial for Psoriasis in China. AC-003, a selective RIPK1 inhibitor, has completed Phase I clinical trials in China and the United States as of August 2023, and is currently undergoing a Phase Ib clinical trial in aGVHD. Accropeutics’ pipeline also includes several assets in the research and pre-clinical stages of development. Accropeutics owns global rights for all of its assets, and boasts 23 issued patents in China, Japan, Korea, US and the EU. For more information, visit www.accropeutics.com

Contacts

Kenneth Gao
SVP, Corporate Development & Strategy
[email protected]

SOURCE Accropeutics

PORTLAND, Ore., March 13, 2025 — Disputed.ai, the most advanced AI-driven chargeback management platform for enterprise merchants, announced today that it has raised $1.12 million in seed funding. This investment will accelerate the company’s mission to redefine how large merchants handle chargebacks through intelligence, automation, and innovation.

Founded by former merchants and technologists who experienced firsthand the challenges of traditional chargeback processes, Disputed.ai combines AI-powered intelligence with deep industry expertise to transform how companies handle chargebacks. The platform is specifically designed for large-scale merchants processing anywhere from 1,000 to 100,000 chargebacks per month, enabling them to manage disputes seamlessly without the need for a large operational workforce.

“Our experience as merchants inspired us to build Disputed.ai,” said Shawn Kelley, Co-Founder & CEO of Disputed.ai. “We created the solution we wished we had, leveraging AI at multiple levels to make intelligent decisions about which chargebacks to fight and how to fight them. Our win-rate & recovery results were the validation, and this funding allows us to more quickly scale and bring our approach to market. We’re committed to transforming enterprise chargeback management.”

Disputed.ai already works with industries that face high dispute volumes, including live entertainment and ticketing, where chargebacks create operational and financial challenges. By leveraging AI-driven automation and industry expertise, they help merchants recover more revenue. In Q4 alone, Disputed.ai recovered 25% more revenue than one leading competitor and 13% more than another.

Beyond performance, Disputed.ai prides itself on its strong relationships with clients, acting as a strategic partner as well as a software provider. The company’s AI-native approach enables merchants to handle thousands of chargebacks without the need for a large operational team, giving leaders the ability to focus on growth rather than dispute management.

“AI has given us a chance to think about chargebacks from first principles, and we’ve developed a platform that takes full advantage of its strengths,” said Andrew Hart, Co-Founder & CTO, “It’s remarkable to see how much value we can create for clients once we get plugged into their data, and how that improves win rates over time.”

“Our mission is to make dispute management effortless, scalable, and highly effective,” added Kelley. “This funding allows us to accelerate our growth, push the boundaries of AI-driven dispute resolution, and help merchants recover more revenue with less operational overhead.”

With this investment, Disputed.ai is accelerating its growth to give enterprise merchants a smarter, more effective way to manage chargebacks. Disputed.ai helps merchants recover more, spend less, and stay ahead in an increasingly complex fraud and dispute landscape.

For more information, visit www.disputed.ai.

About Disputed.ai
Disputed.ai is the leading AI-powered chargeback management platform for enterprise merchants. Built by former merchants, it streamlines chargeback workflows, maximizes win rates, and reduces the operational burden of disputes. Disputed.ai delivers a tailored, scalable solution for large merchants—eliminating the need for a dedicated chargebacks team while driving better outcomes.

SOURCE Disputed, Inc.

FREMONT, Calif., March 13, 2025 — Anyware Robotics, a leader in multi-purpose mobile robotics equipped with embodied intelligence, announced today it has secured $12 million in seed funding. The round is led by GFT Ventures, with participation from Foothill Ventures, Black Forest Ventures, Alumni Ventures, and other investors.

Anyware Robotics is developing highly versatile mobile manipulators to tackle tasks beyond human physical capabilities across industries, whether due to size, reach, precision, speed, or hazardous conditions. Focusing on logistics, their first robot, Pixmo, is designed to unload containers and trucks, sort and palletize, depalletize, pick cases, and load containers – creating a versatile robotic workforce that can be dynamically deployed across the distribution network as operational requirements demand.

“Warehouse operations, particularly container unloading, face critical challenges with worker safety, labor shortages, and operational efficiency,” said Thomas Tang, CEO and co-founder of Anyware Robotics. “Our solution reduces receiving labor expenses by up to 60% and, more importantly, protects workers from injury-prone tasks in harsh conditions where extreme temperatures abound. We’re excited to see Pixmo making a big impact for our customers.”

For unloading, Anyware Robotics equipped Pixmo with an industry first, a patent-pending conveyor accessory, solving the trade-off between flexible and purpose-built automation. Rather than requiring complex pick-and-place movements, Pixmo employs an innovative “pull” motion to the conveyor, significantly increasing speed and reliability, delivering more value to their customers.

Anyware has deployed Pixmo with multiple leading 3PLs, with a focus on clients who process large volumes of ocean containers.

“Our company will handle over forty-five thousand containers in 2025. We’ve sought solutions for years that uphold our efficiency commitments to customers while ensuring a safe work environment for our staff,” said Young Liu, CEO of Western Post US. “We are excited to have Pixmo deployed at our warehouses to unload containers safely, efficiently, and sustainably.”

“What truly impressed us is Anyware’s ability to go from concept to commercial-ready solution with remarkable speed. The team’s deep understanding of warehouse pain points and pragmatic approach, coupled with their proprietary AI technology, positions them to rapidly transform an industry plagued by labor challenges and inefficiencies,” added Jay Eum, Founding Managing Partner of GFT Ventures, who will join the Board of Directors.

Anyware will showcase Pixmo at Promat, where it has been nominated by MHI as a top 3 finalist for the 2025 Best New Innovation award, taking place in Chicago, IL, from March 17^th-20^th. For more information, please visit www.anyware-robotics.com.

Media Contact:

Torsten Schreiber
VP of Marketing
[email protected]

About Anyware Robotics:

Anyware Robotics develops multi-purpose mobile robots, equipped with embodied intelligence, to enhance operations in labor-intensive industries. Pixmo, the company’s first robot, will initially focus on unloading boxes from containers and trucks in a safe, cost-effective, and reliable way. Built for adaptability, Pixmo’s capabilities will expand with future software updates, enabling mobile palletizing, depalletizing, box picking, and truck loading. Founded by AI and robotics industry veterans, Anyware Robotics is headquartered in Fremont, CA. For more information, visit www.anyware-robotics.com.

SOURCE Anyware Robotics

CAMBRIDGE, Mass., March 13, 2025 — Insilico Medicine(“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, announced today that it has successfully secured a $110 million Series E financing led by a private equity fund of Value Partners Group (HKG:0806), one of Asia’s largest independent asset management firms, with strong participation from industry- and technology-focused new investors, as well as continued support from global existing backers.

The funds raised in this round will be directed to advance Insilico’s innovative drug pipeline and AI platform developments. On one side, resources will focus on refining AI models and algorithms, alongside updates and expansions to its state-of-the-art automatic lab to further automate and streamline R&D processes. On the other side, Insilico will focus on advancing the clinical validation of its flagship candidate for idiopathic pulmonary fibrosis treatment and accelerating the exploration of other independently developed and co-developed drug pipelines, driving impactful innovations in healthcare.

“We are excited to partner with Insilico Medicine in its mission to transform drug discovery with AI and automation. With a proven track record and a leadership position in AI-driven drug development, Insilico is at the forefront of transforming the industry. We believe that Insilico’s advancements will not only accelerate the development of life-saving therapies but also redefine the future of biopharmaceutical R&D. This partnership also marks a significant milestone for Value Partners’ private equity strategy and our vision of investing in disruptive innovations that have the potential to reshape industries,” said Dr. Chuen Yan Leung, Partner (Healthcare Investments).

“We are thrilled to announce our $110 million Series E financing—a key milestone that reflects our unwavering commitment to transforming healthcare and the strong confidence of our investors. This round, led by Value Partners and anchored by industry-focused investors, was heavily oversubscribed, drawing exceptional interest from prominent investors,” said Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine. “The funds raised will accelerate the advancement of our drug pipeline and AI platform, further solidifying Insilico’s leadership in this rapidly evolving sector. We remain dedicated to our mission of extending productive longevity to people and are proud to be at the forefront of innovation in healthcare.”

Since its previous financing round, Insilico has achieved substantial progress in both the development of AI platform and drug discovery pipeline and has showcased the ability of its proprietary AI-driven platform to significantly reduce costs and enhance efficiency in the early stages of drug discovery. As its announced key benchmarks for internal preclinical candidate (PCC) programs show: By integrating advanced AI and automation technologies, Insilico has reduced the average time to PCC nomination to just 12-18 months compared to traditional drug discovery methods (typically require 2.5-4 years) , while enabling the synthesis and testing of only 60-200 molecules per program.

Pharma.AI, the proprietary platform developed by Insilico, undergoes major updates twice a year to maintain its technological edge. Built around generative AI and continuously integrating cutting-edge technologies, Pharma.AI provides a comprehensive solution spanning biology, generative chemistry, clinical medicine, and scientific research. As the technology evolves, Insilico has further enhanced Pharma.AI by introducing innovative engines powered by large language models (LLMs), including Nach01, a multimodal foundation model for natural and chemical languages, and Dora, a multi-agent generative research assistant. Recently, Insilico deployed the first bipedal humanoid AI Scientist within Life Star1, its fully robotic lab connected to Pharma.AI, designed to further optimize and automate research workflows.

To date, Insilico has rapidly built a wholly-owned drug discovery portfolio of 30 assets driven by its advanced Pharma.AI platform, with 10 of these assets receiving IND clearance. Among them, the most advanced candidate, Rentosertib (formerly known as ISM001-055), developed for treating idiopathic pulmonary fibrosis (IPF), has progressed through multiple clinical studies with encouraging results. In a completed Phase IIa clinical trial, Rentosertib demonstrated favorable safety and tolerability across all dose levels, along with dose-dependent response in forced vital capacity (FVC), after only 12 weeks of dosage.

In addition, Insilico has established a sustainable revenue stream through its business model centered on out-licensing deals for its pipelines. The company has secured four pipeline out-licensing agreements with Fosun Pharma, Exelixis, and Menarini, collectively valued at over $2.1 billion. Concurrently, Insilico has initiated multiple drug discovery and development collaborations with industry partners, including Sanofi, Saudi Aramco, Therasid Bioscience and others, with the collected value of over $1.4 billion. Many of these partnerships have reached milestones, resulting in milestone payments to Insilico, further contributing to the company’s growing financial performance.

With the successful completion of its Series E financing, Insilico will further accelerate the advancement of AI-powered biopharmaceutical research and development, strengthen collaboration across the industry value chain, and drive the application of its cutting-edge AI platform in diverse scenarios within the life sciences sector through flagship use cases.

About Insilico Medicine

Insilico Medicine, a global clinical stage biotechnology company powered by generative AI, is connecting biology, chemistry, medicine and science research using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. For more information, please visit www.insilico.com.

About Value Partners Group Limited

Value Partners, one of Asia’s leading independent asset management firms, seeks to offer world-class investment services and products. Since its establishment in 1993, the Company has been a dedicated, specialist value investor in Greater China and Asia. In November 2007, Value Partners Group became the first asset management firm to be listed on the Main Board of the Hong Kong Stock Exchange (Stock code: 806 HK). In addition to its Hong Kong headquarters, the firm operates in Shanghai, Shenzhen, Singapore and London. Value Partners’ investment strategies cover equities, fixed income, multi-asset, alternatives, real estate and quantitative investment solutions, for institutional and individual clients in Asia Pacific, Europe and the United States. For more information, please visit www.valuepartners-group.com.

SOURCE Insilico Medicine

DENVER, March 13, 2025 — Konvoy, a leading venture capital firm specializing in gaming and interactive entertainment, has partnered with their portfolio company, Rocket Science, a premier technical services provider for game developers, to release the 2025 Game Developer Survey. This in-depth report compiles insights from 155 game developers, shedding light on the shifting landscape of game development, technology adoption, and monetization strategies. 

The report highlights a notable shift in game engine preferences, with Unity remaining a dominant force but seeing increased competition from open-source alternatives like Godot and Stride, particularly among smaller studios.

Artificial intelligence continues to play a role in game development, but enthusiasm for AI-generated content is cooling. While many studios experimented with generative AI in 2024, the report finds that developers are now focusing AI applications on workflow automation and backend efficiencies rather than creative content generation. 

The survey also uncovers major shifts in user acquisition and monetization strategies. Possibly due to changes in Apple’s pricing model, many studios are reducing their reliance on Apple Search Ads, turning instead to platforms like Tenjin and Branch for more cost-effective user acquisition solutions. 

In the multiplayer space, studios are reevaluating backend technology choices. Despite launching new product offerings, Photon has seen a decline in adoption, while Edgegap is gaining traction following its Epic Online Services partnership, signaling a growing preference for flexible and scalable multiplayer infrastructure solutions. 

To discuss these findings, Konvoy and Rocket Science hosted an exclusive industry panel on March 11th, featuring Karthik Bala (CEO, Velan Studios) and Mark James (CTO, Endava Games), moderated by Brian Corrigan (Co-Founder, Rocket Science) and Jackson Vaughan (Managing Partner, Konvoy Ventures). 

“This year’s survey confirms what we’ve been hearing from developers: the game development landscape is shifting faster than ever,” said Brian Corrigan, Co-Founder of Rocket Science. “From changes in preferred engines to evolving multiplayer infrastructure, the industry is undergoing a massive transformation. Understanding these trends is critical for developers navigating an increasingly complex ecosystem.”

The survey findings reflect a broader industry pivot. The rise of open-source engines highlights a demand for cost-effective and flexible development tools, particularly among independent studios. At the same time, developers are reassessing AI’s role in game creation, shifting their focus toward practical AI applications like QA automation and localization. With user acquisition and monetization strategies evolving rapidly, studios are adjusting their approaches to maximize engagement while controlling costs. 

“Partnering with Rocket Science allowed us to bring an incredibly deep level of technical expertise to our inaugural game developer survey,” said Jackson Vaughan, Managing Partner at Konvoy Ventures. “These insights help developers and industry leaders navigate an evolving landscape and make informed decisions about the tools and platforms shaping their businesses.” 

The full 2025 Game Developer Survey is now available. To access the report, please visit: (link https://www.konvoy.vc/reports/game-developer-survey-2025). 

About Konvoy:
Konvoy is a thesis driven venture capital firm. We invest in the platforms and technologies at the frontier of gaming.
Learn more at (https://www.konvoy.vc/) 

About Rocket Science:
Rocket Science Group builds top-tier studios that combine specialized expertise with operational excellence.
Learn more at (https://www.rocketscience.gg). 

SOURCE Konvoy

SAN JOSE, Calif., March 13, 2025 — PRE Security, the world’s first AI Native Predictive Security Operations (SecOps) company, has been recognized with multiple Cybersecurity Excellence Awards, further cementing its leadership in AI-driven security innovation. Among the prestigious honors, co-founder John “JP” Peterson has been named the AI Security Innovator of the Year for 2025.

AI Security Innovator of the Year: John “JP” Peterson
“With PRE Security being one of the pioneering companies leading cybersecurity into the AI era, it’s no surprise that John has been recognized as the AI Security Innovator of the Year,” said Paul Jespersen, co-founder of PRE Security. “JP has a proven track record of innovation, technical leadership, and transforming cutting-edge security product concepts into market-ready solutions—culminating in his work here at PRE Security.”

Holger Schulze, founder of Cybersecurity Insiders and organizer of the Cybersecurity Excellence Awards, extended his congratulations as well: “As we celebrate a decade of recognizing excellence in cybersecurity, we are proud to honor John Peterson for his innovation, commitment, and leadership. His contributions set a powerful example for the entire industry.”

Additional Cybersecurity Excellence Awards for PRE Security
Beyond Peterson’s individual recognition, PRE Security was also awarded in the following categories:

• Most Innovative Cybersecurity Company (10-49 Employees)
• Best AI SecOps Solution
• Excellence in Cybersecurity Innovation

“These awards validate our leadership in AI-driven cybersecurity, particularly in Generative and Agentic AI,” said Peterson. “Our patent-pending technologies, such as Parserless™ data ingestion and Next Alert Prediction, and our industry first CyberLLM™ are pushing SecOps into the future. While I am honored to receive the AI Security Innovator of the Year award, this recognition truly reflects the dedication and ingenuity of our entire PRE Security team.”

PRE Security’s Continued Growth and Leadership Expansion
PRE Security’s rapid growth has been fueled by significant product advancements and the growing world class team. To build on this momentum, the company has made key leadership appointments:

• Leo Versola has been promoted to Chief Product Officer, responsible for driving product vision and development.
• Jens Andreassen has joined as Vice President of International to help lead the expansion of our international teams. Prior to this, Andreassen served as Vice President of International at Fortinet and later as CEO of Lastline (which was acquired by VMware,) among other leadership roles in the cybersecurity industry.

“Over the years I’ve been involved with numerous companies and startups,” Andreassen shared. “However, it’s rare to see the channel community respond so overwhelmingly positively to a new technology as we’ve seen with PRE. I’m excited to be part of the team as we lead cybersecurity into the AI era.”

About PRE Security
PRE Security is redefining cybersecurity with its AI Native SecOps solutions, delivering advanced detection, predictive security analytics, and automation. Built on Generative, Predictive, and Agentic AI innovations, PRE Security eliminates the pain points and shortcomings of traditional SIEM and XDR solutions. Founded by cybersecurity veterans John “JP” Peterson and Paul Jespersen, PRE Security is headquartered in Silicon Valley.

Learn more at www.presecurity.ai.

Media Contact

Paul Jespersen
Email: [email protected]
Phone: 408-218-9668

SOURCE PRE Security

Investment signals strong confidence in Rep Data’s leadership, fueling investment in ground-breaking technology, expansion of tech-enabled research services and strengthening its position as the premier partner for high-quality research data.

NEW ORLEANS, March 13, 2025 — Rep Data, the industry’s leading provider of high-quality research data and fraud prevention solutions, today announced a growth investment by Mountaingate Capital. This will accelerate the company’s vision, strengthening its market-leading Research Desk and Research Defender platforms, while expanding its capabilities to better serve global brands, insight firms, and consultancies.

“This investment is a testament to the strength of our vision, our team, and the impact we are making in defining data quality for the market research industry,” said Patrick Stokes, CEO and founder of Rep Data. “From day one, we set out to raise the standard for research data integrity, and this growth investment enables us to push even further—advancing our fraud prevention technology, expanding our tech-enabled services, and ensuring that researchers worldwide can trust the data they collect. This marks an inflection point for Rep Data and the insights industry as a whole.”

Strengthening data integrity and efficiency in insights

Rep Data is an industry leader in data quality with its Research Defender platform, a sophisticated fraud detection technology designed to safeguard research integrity. The platform analyzes billions of data points annually, identifying and blocking fraudulent responses from tech-enabled fraudsters, professional survey takers, and click farms before they impact research studies. Research Defender processed 2.9 billion security scans in 2024, playing a pivotal role in shaping the industry’s fraud prevention standards and protecting research at an unprecedented scale.

Beyond fraud detection, Rep Data’s Research Desk platform improves speed to insights by integrating real-time fraud controls, multi-source sampling, and automated reconciliations into a seamless, centralized solution. By combining its expanding global sources with Research Defender’s fraud mitigation capabilities, Research Desk enhances data reliability, reduces inefficiencies, and strengthens research accuracy for clients.

Expanding service capabilities and strategic partnerships

By broadening its services and streamlining research execution, Rep Data is positioned to help clients move faster, reduce operational complexity, and drive more meaningful business outcomes with confidence in their data.

“We are extremely excited to partner with the Rep Data team. Rep Data is at the forefront of protecting research integrity with its cutting-edge Research Defender platform, setting a new standard for fraud prevention in the industry,” said Sue Cho, Managing Director of Mountaingate. “The company’s ability to analyze billions of data points and proactively eliminate fraudulent responses ensures that market researchers can rely on high-quality, trustworthy data. Rep Data’s rapid growth, innovative technology, commitment to data integrity, and impressive management team position it as a clear industry leader, with significant opportunities to further expand its impact and drive accelerated growth both organically and through strategic acquisitions.”

With this growth investment, Rep Data continues to advance the cause of data quality, efficiency, and execution; strengthening its position as a trusted partner, providing high-quality, reliable data for critical research studies.

Canaccord Genuity, a global investment bank, served as the exclusive advisor to Rep Data on this transaction. Jones Walker LLP represented Rep Data in the transaction and Morrison & Foerster LLP represented the buyer.

About Rep Data
Rep Data is a technology-driven data and insights partner, helping insights professionals streamline insights initiatives with a focus on data quality and consistent execution. Partnering with market research agencies, consultancies, Fortune 500 corporations, advertising and brand strategy firms, universities, and public relations agencies, Rep Data delivers real, reliable, and fraud-free research data at scale. Its solutions include: Research Desk, a centralized research platform that enhances efficiency and data quality; and Research Defender, an advanced fraud prevention system that conducts 2.9 billion security scans annually to protect data integrity. Through tech-enabled services, Rep Data provides expert support to help organizations scale with confidence. Committed to high-quality data and innovative tech-enabled solutions, Rep Data is redefining market research to drive faster, more reliable insights. For more information, visit www.repdata.com.

About Mountaingate Capital
Mountaingate Capital is a Colorado-based private equity firm that specializes in partnering with founders and entrepreneurial companies to accelerate growth and build industry leaders. Mountaingate’s focus on organic growth, coupled with its customer-centric buy-and-build approach for add-on acquisitions, and shared equity ownership with management, creates more value for the end customer, while forging stronger, more collaborative, and more successful investment partnerships with management teams. With over $1.4 billion of assets under management, Mountaingate targets investments in marketing services, business services, specialty manufacturing and distribution. For more information on Mountaingate, please visit www.mountaingate.com.

Media contact: Marie Melsheimer, [email protected], +1-541-815-3951

SOURCE Rep Data

The company will expand its state-of-the-art visual generative AI platform to bolster creation of scalable AI-driven visual products for enterprises without infringing on privacy or copyright.

NEW YORK, March 13, 2025 — Bria, the enterprise visual gen AI platform built on 100% licensed data, announced today that it has closed $40 million in Series B funding, bringing total capital raised to $65 million. Led by Red Dot Capital, with participation from Maor Investment, Entrée Capital, GFT Ventures, Intel Capital, and In-Venture, the investment will be used to scale the company’s visual generative AI platform, enabling enterprises to leverage the innovative technology risk-free to develop on-brand content. Bria will also use the funds to widen the application of its patented attribution engine beyond images to music, video, and text generation.

One of the most significant criticisms of AI today is its seeming lack of respect for existing IP and proper protocols for licensing. With this investment, Bria looks to change that, creating a whole new IP ecosystem wherein businesses can access licensed IP content from media conglomerates and studios for use in commercial gen AI creations, with built-in compliance. Bria’s Visual Generative AI platform empowers businesses to create predictable, controllable, and on-brand content that aligns with their visual language while supporting e-commerce use cases, identity preservation, and seamless content editing and fine-tuning.

“Since its inception, Bria’s mission has been to bridge the accountability gap between organizations and Gen AI through transparency, accessibility, and control,” said Dr. Yair Adato, Bria Founder and CEO. “While our patented attribution technology has instilled trust in AI systems, facilitating responsible, controlled access to coveted IP content will change the game. Enterprises can use our source code and API platform to integrate visual generative AI inside their products and access previously untouchable premium branded content. By broadening our attribution offering to all types of content, including music, video, and text, we are helping to usher in a truly sustainable creative economy.”

Bria’s Generative AI models are trained exclusively on licensed data, with built-in guardrails allowing enterprises to carve out the risks and barriers to Gen AI adoption and capitalize on infinite content creation. Bria developed a patented attribution engine that bridges the generative output and the training dataset, so data owners are programmatically compensated according to their overall influence on each generated output. Bria has over 30 data partners and is growing, including Getty Images, Envato, Alamy, Freepix, Depositphoto, and more. This Spotify-inspired commercial model ensures no copyright or privacy infringement and upholds transparency in line with evolving AI regulations.

Bria’s platform offers developers complete flexibility, including visual foundation models, source code and weights, and a fine-tuning API. It allows users to build wherever and whenever necessary to achieve their business goals. Bria integrates with AWS SageMaker, Azure AI Foundry, AI marketplaces, ComfyUI, Fal.AI, and more while offering plug-ins for Photoshop and Figma. Developers own their content machines, IP, and data wherever they build.

“The potential of generative AI in the enterprise space—where efficiency and creativity drive ROI—is immense,” said Danielle Ardon Baratz of Red Dot Capital. “Bria is redefining how enterprises create and personalize visual content at scale with its enterprise-grade platform, designed for control, predictability, and modularity. Bria is setting a new standard in AI-driven content generation. We are excited to support their journey as they help bring Gen AI to more organizations in a risk-free manner, how and where they want, while pioneering an innovative business model that keeps content creators compensated and incentivized”.

This round comes nearly one year after Bria closed its Series A funding in March 2024. Since then, Bria has solidified its position as a Responsible leader in AI-generated visual content through strategic alliances with technology giants, including Nvidia, Microsoft, and AWS. It was named an AWS Design Partner of the Year. Bria has also forged partnerships with global brands across high-growth sectors, such as media, gaming and entertainment, retail and CPG, marketing agencies, and creative tools.

About Bria

Bria’s visual generative AI platform enables developers, product teams, and enterprises to build commercial-ready content. Our foundation models, trained on 100% licensed data from 30+ partners, ensure legal compliance with proper attribution to data owners and artists.

Bria provides technical teams full access to source code and weights, production-grade APIs/SDKs, and the flexibility to incorporate these AI building blocks into their preferred builder environments. Bria’s pre-built pipelines offer the fastest path to market-ready visual AI implementation. At the same time, advanced teams leverage our ControlNets, LoRAs, and LCMs for pixel-perfect precision and maximum control over visual outputs. Bria offers complete IP/privacy indemnity and EU AI Act-compliant architecture with flexible commercial terms that leverage existing cloud commitments.

Leading advertising, gaming, media, and retail enterprises rely on Bria to deliver precise, on-brand visual content at scale. Looking ahead, Bria is pioneering the future of premium content generation—where visual AI, data ownership, and artistic contribution coexist to create sustainable value. For technical documentation, visit Bria.ai.

Media Contact

Sarah Small
Headline Media
[email protected]
IL:+972 052 214 8601
US:+1 929 255 1449
UK:+44 203 807 1858 

SOURCE Bria